Heat shock factor 1 (HSF1-pSer(326)) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report

Bortezomib (BTZ) was recently evaluated in a randomized phase 3 clinical trial by the Children’s Oncology Group (COG) that compared standard chemotherapy (cytarabine, daunorubicin, and etoposide [ADE]) vs standard therapy with BTZ (ADEB) for de novo pediatric acute myeloid leukemia (AML). Although t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Hoff, Fieke W., van Dijk, Anneke D., Qiu, Yihua, Ruvolo, Peter P., Gerbing, Robert B., Leonti, Amanda R., Jenkins, Gaye N., Gamis, Alan S., Aplenc, Richard, Kolb, E. Anders, Alonzo, Todd A., Meshinchi, Soheil, de Bont, Eveline S. J. M., Bruggeman, Sophia W. M., Kornblau, Steven M., Horton, Terzah M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2021
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7907722/
https://ncbi.nlm.nih.gov/pubmed/32959058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005208
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados